Ricky Lijing Sun

Ricky Lijing Sun is a Partner and Managing Director at Bain Capital Life Sciences in Boston, United States. He focuses on seed through Series B investments in therapeutics and life-science platforms, typically deploying check sizes between $100,000 and $5 million from the firm's $3 billion fourth fund. Prior to joining Bain Capital, Sun served as Director of Corporate Development and Strategy at Biogen from 2013 to 2016 and held Vice President and senior healthcare analyst roles at BlackRock and Citadel. He began his career as a senior scientist at Ironwood Pharmaceuticals after earning a PhD in chemistry and chemical biology from Harvard University. Sun currently serves on the boards of Savara, Emalex, Avistone, and Tenacia, having previously held directorships at Arcutis and Annexon. His career bridges foundational scientific research with extensive corporate development and healthcare equity investment expertise.